24 January 2022 - The third approval for bimekizumab worldwide reinforces UCB’s commitment to bring new treatment options to the global dermatology community.

UCB today announced that the Japanese Ministry of Health, Labor and Welfare has granted marketing authorisation for Bimzelx (bimekizumab) for the treatment of plaque psoriasis, generalised pustular psoriasis and psoriatic erythroderma in patients who are not sufficiently responding to existing treatments.

Read UCB press release